Hynes Keller & Hernandez, LLC, a national law firm dedicated to providing exceptional legal services in shareholder litigation, with a focus on corporate malfeasance and breaches of fiduciary duty, is investigating potential claims against the Board of Directors of Northwest Biotherapeutics, Inc. (“Northwest” or the “Company”) (NASDAQ: NWBO) concerning possible breaches of fiduciary duty and other violations of law. The investigation concerns actions by Northwest’s Board of Directors that have allegedly caused the Company to issue improper statements regarding test results.
Specifically, the prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct. “I have read the information that the company has put in the public domain. It is extremely unusual and inappropriate,” said Dr. Aman Buzdar, vice president of clinical research at MD Anderson, a unit of the University of Texas system. Northwest Bio has issued five press releases and held a conference call in the past month to disclose preliminary and unconfirmed results from individual cancer patients who have had single, inoperable tumors injected repeatedly with DCVax-Direct. But Buzdar said investigators at MD Anderson and the two other hospitals conducting the DCVAX-Direct study have not reviewed or analyzed data at all because patients are still being enrolled and treated.
Shareholders interested in seeking to recover damages on behalf of Northwest and to implement corporate governance measures designed to prevent future misconduct should contact the firm.
If you hold NWBO shares and you would like to discuss your legal rights, please email the firm at email@example.com.You can also contact us by calling Michael J. Hynes at (610) 994-0292 or by sending an e-mail firstname.lastname@example.org.